Objective: The objective of the study was to compare the effectiveness and safety of intravenous etomidate against midazolam in procedures which required sedation and analgesia in our emergency department. Methods: The study was conducted in the emergency department of Queen Elizabeth Hospital from 1st November 2005 to 30th June 2006. Adult patients who required procedural sedation and analgesia were recruited and randomised into two groups, in which either etomidate or midazolam was used as the sedative agent. Vital parameters and depth of sedation were closely monitored until they regained full consciousness. Results: a total of 87 patients were recruited and randomised into study and control groups, of which 78 patients completed the study and were analysed − 36 patients were in the midazolam group whereas 42 patients were in the etomidate group. There was no statistical difference in mean age, mean weight and procedures between the two groups. Mean time for onset of action was 1.8 minutes for the etomidate group versus 3.4 minutes for the midazolam group (p=0.003). There were no significant differences in total procedure time, total length of stay, pain score, satisfaction score and adverse effects. Conclusion: Etomidate achieved adequate depth of sedation for painful procedures in significantly shorter time than midazolam. There were no differences in procedure time, length of stay, pain relief and patient's satisfaction between the two drugs. 
Introduction
The use of sedative agents is frequently required for painful procedures performed in the emergency department (ED). Any procedure causing pain can be an indication for procedural sedation and analgesia (PSA).
C o n v e n t i o n a l l y, m i d a z o l a m , a s h o r t -a c t i n g benzodiazepine, has been widely used for painful procedures in many EDs. Etomidate, an imidazole derivative with rapid onset and brief duration of action, is potentially attractive for using as a sedative agent. It was first used in the United States in 1982. [1] [2] [3] It is most commonly used as an induction agent for rapid sequence intubation (RSI) but has recently been studied as a sedative agent for use in procedural sedation because of its fast onset, short duration of action, and limited side effects. [4] [5] [6] [7] [8] [9] A recently published prospective study also showed that etomidate had significant reduction in the mean time of sedation as compared to midazolam. 9 The authors had enrolled a total of 45 patients (24 randomised to etomidate; 21 randomised to midazolam) only and discontinued the study at midpoint. Nevertheless the study was not blinded and did not demonstrate a significant reduction in the total length of stay in the ED, i m p r o v e m e n t i n p a i n c o n t r o l a n d p a t i e n t satisfaction because the authors terminated the study in the mid-term analysis when the reduction in mean sedation time had been statistically significant. We conducted a prospective, doubleblinded, randomised clinical trial to compare the action, effectiveness, patient safety and satisfaction of etomidate against midazolam for PSA.
Methods
The study was conducted from 1st November, 2005 to 30th June, 2006 in the Accident and Emergency Department of Queen Elizabeth Hospital.
Patient selection
Adult patients of age at or above 18 years who required PSA were eligible. In our department, the most common indications for PSA would be closed reduction of joint dislocation or closed reduction of bony fracture.
The exclusion criteria were as follows: -paediatric patients less than 18 years old -geriatric patients more than 80 years old -patients who are unable to give informed consent -pregnancy -patients who may be haemodynamically unstable, e.g. severe anaemia, hypotension, multiple trauma -patients who have underlying uncontrolled cardiopulmonary illnesses, e.g. asthmatic attack, chronic obstructive airway disease, congestive heart failure -patients who may be neurologically unstable, e.g. under central nervous system depressant effect of drugs or alcohol, head trauma -patients who require analgesia for pain control only, without sedatives -patients who require sedation solely for the purpose of managing behavioural emergencies -known allergy to fetanyl, etomidate or midazolam -patients who refuse to participate in the study or withdraw at any interval
Procedures
An informed written consent was obtained by the attending doctor (Appendix 1a and 1b). A standardised check list (Appendix 2) would direct the preparation of the patient. One clinician and a nurse (N1) were responsible for the PSA. The procedure was conducted in Cubicle 6A which was close to the resuscitation room of our ED.
Patients were randomised into two groups by a computer-generated random number table in blocks of four. Each sealed opaque envelope contained the drug name of either midazolam or etomidate, instruction sheet for drug preparation and drug labels. An independent nurse, who would not be involved in the procedure, drew an envelope, prepared and labelled the syringe. The etomidate syringe would contain 0.1 mg/kg etomidate diluted with normal saline solution to 10 ml. The midazolam syringe would contain 0.05 mg/kg midazolam diluted to 10 ml. The independent nurse, after having prepared the syringe of sedative agent accordingly, would label and cover the syringe with the patient's gum label, drug code and identical syringe cover. The study syringe, all identical on external appearance, and the re-sealed envelope would be given to the assisting nurse (N1), who did not know its content.
At the beginning of PSA, the clinician gave 1 mcg/kg of intravenous fentanyl to the patient for analgesia. A marker for the start of procedure was required. The time of fentanyl administration would mark the beginning of the PSA, as "time zero" (i.e. T0). The study drug was given after fentanyl. The blinded sedative agent was administered by the clinician via the intravenous route. The time from "time zero" to the start of procedure would be defined as the time for onset of action (T1).
N1 recorded the time, oxygen saturation and respiratory rate, blood pressure and pulse, at 5-minute intervals throughout the procedure. The adequacy of depth of sedation was assessed according to the Ramsay sedation score as shown in Table 1 . The score of 2 or 3 was aimed for at the start of the procedure. The Aldrete post-anaesthetic recovery (PAR) scoring system (Appendix 3) was used to monitor the depth of sedation and the recovery from sedation. Close monitoring and observation of vital signs were continued until the patient regained full consciousness. The time from T0 to full recovery of baseline consciousness would be defined as the total PSA duration (T2). The aftercare management and followup of the patients would proceed according to individual clinical conditions as appropriate.
The PSA record (Appendix 4) was completed by nurses (N1). The time from "time zero" to the time of patient disposal was defined as the total length of stay (T3). The pain relief was mainly achieved by intravenous fentanyl which was used in both groups. However, we were also interested in whether there would be any additive effect on pain relief with either sedative agent. Pain score and patient satisfaction were documented with separate 100-mm visual analogue scales (VAS) upon completion of the study by the attending clinician. If adequate sedation was not achieved by the initial bolus of sedative agent, the patient would be dropped out from the study and further additional sedative drug would be given according to the clinician's choice.
Patient safety
Procedural sedation and analgesia should ideally take place in a well-controlled environment, with full resuscitation equipments. The emergency physicians who conducted the procedure had attended the Advanced Cardiac Life Support (ACLS) course and basic air way management workshops or else be supervised by a qualified senior. Senior clinicians who were competent in advanced airway management would be around when help was needed. Close monitoring of oxygen saturation, blood pressure and pulse, and depth of sedation was performed by nurses throughout the p r o c e d u re b e f o re t h e a c t i o n o f m i d a zo l a m , etomidate and fentanyl wore off.
Adverse events such as nausea, vomiting, pain at injection site, hypotension, oxygen desaturation, use of antidote (flumazenil, naloxone) or inotropic agent (adrenaline), use of bag-valve-mask ventilation, and intubation would be recorded accordingly. Discharge advice together with a written post-sedation instruction sheet (Appendix 5) would be given to the patient upon discharge.
Outcome measures
Primary outcome measures were time to onset, time for procedure and total time of stay in the ED. Secondary outcome measures were pain control, patient satisfaction and adverse effects. The sample size calculation was based on the assumption that detecting at least a 45-minute difference between the groups in total length of stay in the ED to be of clinical significance in the improvement of quality of care. With reference to a study comparing etomidate and midazolam for PSA in ED, 9 assuming a power of 80%, a level of significance of 5%, standard deviation of 96 minutes, it was estimated that 38 patients would be required in each arm. The data were analysed by the chi-square technique for categorical variables and if the number of patients in any cell was less than five, Fisher's exact test was used. A two-tailed p value of 0.05 was used to define statistical significance for differences between groups and to calculate confidence intervals around differences in sample means. SPSS for windows, version 12.01b (SPSS Inc., Chicago, IL) was used for statistical analysis.
The study was approved by the Research Ethics Committee of Kowloon Central Cluster.
Results
The patient flow chart was illustrated in Figure 1 . A total of 87 patients were recruited and randomised into study and control groups. However, only 78 patients completed the study; 36 patients in the midazolam group and 42 patients in the etomidate group. The mean age, weight and sex distribution are shown in Table 2 . The number and type of procedure are illustrated Figure 2 . Most of the procedures that required PSA were closed reduction of dislocation in limbs, with or without associated fracture. There were three jaw dislocations that required the use of PSA and they were eventually randomised into the midazolam group (procedure marked as "others").
The mean T1 was 3.4 minutes for the midazolam group versus 1.8 minutes in the etomidate group (p=0.003) ( Table 3) . Thus, the time for onset of drug action was significantly shorter in the etomidate group. The mean T2 was 11.0 minutes in the midazolam group versus 9.1 minutes in the etomidate group (p=0.112). There was no statistical difference in the mean procedure times. The mean T3 was 169.6 minutes and 278.9 minutes in the midazolam group and etomidate group respectively (p=0.276). There was no significant difference in total length of stay. The medians of T3 were 79.5 minutes for the etomidate group and 82.5 minutes for the midazolam group. When we looked at the results of T3, the results were highly skewed.
Pain score was recorded with VAS and both groups showed similar effectiveness. Patient satisfaction was also similar in both groups. Adverse complications such as desaturation, hypotension, nausea and vomiting would be recorded in the procedure record. None of the patients in both groups had a drug-related serious adverse event. Six patients from the midazolam group failed to complete the study because the initial midazolam bolus could not achieve adequate sedation. There were three dropout patients from the etomidate group who required admission for definitive management of other medical problems.
Discussion
From this study, etomidate was shown to achieve an adequate depth of sedation for carrying out a painful procedure in significantly shor ter time than midazolam. In carrying out a procedure, the time recording and the marker of "time zero" were essential for meaningful analysis and interpretation since both drugs were supposed to be short-acting. However, via an intravenous line, the time lag for administering the second drug would be minimal.
T2 might be affected by other variable factors such as the complexity of the procedure and the physician's experience. T3 would be affected by waiting for retaking post-reduction X-rays, availability of the physician-in-charge for re-assessment before discharge and so on. As a matter of fact, even a quicker start of procedure might not subsequently predict a reduction in the total procedure time and length of stay. There were some limitations of this study. T1 was not the "true" action time because we used injection of fentanyl to mark the "time zero" for convenient nursing monitoring. Since there was a difference in the injection time, it might affect the results of T1 despite the small magnitude of time lag via an intravenous route. Blinding of the physician was technically difficult in practice. This might have been corrected by administrating the study drug by a nurse instead of the physician. Preparation of the drugs would require adaptive period of time which eventually was shortened after the nurses got familiar with the settings. Drawbacks of drug labelling would lead to extra time for drug preparation, improper physician blinding, and hence affecting the results. Etomidate was a milky suspension while midazolam was clear and the identity of the study drug would therefore be easily uncovered.
Some dropouts resulted from inadequate midazolam dosage. From past experience, midazolam was used cautiously with titration of dose or slow infusion in elderly patients for fear of respiratory depression. In our study, midazolam was given as a bolus dose and hence it was adjusted to a relatively smaller dose for patient safety. As expected, those dropouts were observed to be young males.
In our study, none of the patients experienced drugrelated serious complications. Adverse effects of midazolam like hypotension, desaturation, apnoea, and myoclonus had been reported in other series. From the literature, midazolam may cause respiratory depression which would be enhanced by opioids. Other adverse effects included headache, nausea, emesis and a decrease in systemic vascular resistance resulting in hypotension. Desaturation and apnoea had been observed as common sedation complications of midazolam. However only a minority required bagvalve-mask ventilation with 100% oxygen and no endotracheal intubation was required. [5] [6] [7] [8] [9] In our study, the mean age of patients in the midazolam group was 57 (SD=23). They might have tolerated midazolam without any significant side effect even when it was given in a bolus dose.
Etomidate was reported to produce intermittent myoclonic jerks especially at higher doses when it was used for rapid sequence induction. When it was used in procedural sedation where smaller doses would be adequately effective, the muscular pain had not been reported in this setting. 10 Etomidate has been reported to cause adrenal insufficiency by either a continuous infusion or multiple doses. This adrenal dysfunction was caused by inhibition of the enzyme 11-β-hydroxylase that converted 11-deoxycortisol to cortisol.
11
A prospective trial found that there was an initial decreased serum cortisol response to exogenous cosyntropin in ED patients receiving single dose etomidate. However, all cortisol levels remained within normal limits, and all measurable adrenocortical dysfunction resolved within twelve hours. 12, 13 Larygospasm had not been seen in previous studies using etomidate of smaller than RSI dosage for procedural sedation, i.e. 0.1 mg/kg to 0.2 mg/kg. [5] [6] [7] [8] [9] A number of drug combinations for procedural sedation and analgesia had been used in different emergency departments. The usual combinations included one kind of benzodiazepine and one kind of narcotic analgesic. There were numerous variations in both regime and dosage with respect to the choice of drugs which again varied from physician to physician and from department to department. Nevertheless, emergency physicians all have a similar goal to achieve the targeted treatment in a relatively comfortable manner for patients and themselves.
Conclusion
Etomidate was shown to achieve adequate depth of sedation for painful procedures in significantly shorter time than midazolam. There was no difference in procedure time, length of stay, pain relief and patient satisfaction between the two drugs. The choice of agents would depend on physician preference and drug availability.
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Study on Etomidate and Midazolam in Procedural Sedation and Analgesia (Patient's information sheet)
What is this study about? This study is conducted by the Accident and Emergency Department of QEH. This study aims to examine whether Etomidate will result in a quicker recovery and quicker discharge from the A&E than the conventional agent (Midazolam). Etomidate is traditionally used in rapid sequence induction by anaesthetists. Many recent studies have shown its effectiveness in light sedation for use in the emergency department. This can be applied to any painful procedures, e.g. closed reduction of joint dislocation or closed reduction of fracture with immobilisation.
What will the procedure be? When we decide that you are eligible for the study, your consent will be obtained. There will be no difference in the treatment procedure you receive, except the use of sedative agent. You will be given either one of the study sedative agents. It will be prepared by the nurse and you will be blinded to the nature of the agent. The procedure will be performed in the usual manner. You will be observed in the Emergency Ward after the procedure. You will need to fill in a questionnaire about the pain of the procedure and the satisfaction about the overall procedure before you go home.
Would there be any risk?
Adverse effects Etomidate may have intermittent myoclonic jerks and loss of protective airway reflex in larger doses. Midazolam has side effects of respiratory depression, hypotension, nausea, vomiting. An antidote is available to reverse its effects when oversedation occurs.
Advantage
Etomidate has the advantages of rapid onset of action, shorter recovery time, less hypotensive and minimal cardiovascular effects than Midazolam. Antidote is available for Midazolam oversedation. A small dose will be used for sedative purpose. You will be closely monitored for any adverse effects.
You can withdraw from this study at any time. Your withdrawal will not affect the care you receive in our department. The personal data will be kept confidential. Systolic blood pressure BP ± 20% of preanaesthetic level 2 BP ± 20%-50% of preanaesthetic level 1 BP ± 50% of preanaesthetic level 0 
Level of consciousness
